A Phase 2 interventional study of SEP-363856 in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 30 sites in 5 countries. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2024-07-05.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.
Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 7th largest by enrollment, is one of 2 that started in 2017, is one of 2 in phase 2, and was the 4th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:
Otsuka Pharmaceutical Co., Ltd. · Sites in Japan
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 11 · Phase 2 3 · Phase 3 10
First in 2013; this study’s year is marked. 2 started in 2017.
This study's enrollment of 157 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 83 across the 23 interventional studies. Of the 21 that completed or were terminated, 8 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 23 have an industry lead sponsor. The 3 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
120 studies in Schizophrenia by Otsuka Holdings Co., Ltd.: 3 open now, 4 under way, 3 of them phase 3. Of 111 finished, 64 (58%) have results posted.
Among the 120 studies in Schizophrenia by Otsuka Holdings Co., Ltd., this one is the 51st largest by enrollment of the 111 interventional ones that give a count, is one of 10 that started in 2017, is one of 9 in phase 2, and was the 75th registered.
Otsuka Holdings Co., Ltd.’s Schizophrenia studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 23 studies testing SEP-363856 in Schizophrenia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 120 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia
This is a 26 week, multiregional, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201 (NCT02969382) Subjects received open-label SEP-363856 50 mg/day from Day 1 through Day 3, and then received flexible dosing of SEP-363856 (25, 50, or 75 mg/day) for the rest of the trial.
No statistical hypothesis tests will be performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subject must give written and privacy authorization prior to participation in the study and able to comply with the protocol, in the opinion of the investigator.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SEP-363856 capsule (25 mg, 50 mg, or 75 mg) once daily
Drug: SEP-363856
One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
The Incidence of Overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) Leading to Discontinuation
Number of Participants with overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) leading to discontinuation
Time frame: From first dose of study drug to last study visit (27 weeks)
Frequency of Suicidal Ideation (SI) and Suicidal Behavior (SB) Using the Columbia - Suicide Severity Rating Scale (C-SSRS)
Number of participants with suicidal ideation (SI) and suicidal behavior (SB) using the Columbia - Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a tool designed to systematically assess and track suicidal behavior and suicidal ideation for life time, one month prior to the screening visit for suicidal ideation and 6 months prior to the screening visit for suicidal behavior, and throughout the study. The strength of this suicide classification system is in its ability to comprehensively identify suicidal events while limiting the over-identification of suicidal behavior.
Time frame: Overall post Open-label Baseline treatment period (26 weeks)
Severity of Suicidal Ideation (SI) and Suicidal Behavior (SB) Using the Columbia - Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a tool designed to systematically assess and track suicidal behavior and suicidal ideation for life time, one month prior to the screening visit for suicidal ideation and 6 months prior to the screening visit for suicidal behavior, and throughout the study. The strength of this suicide classification system is in its ability to comprehensively identify suicidal events while limiting the over-identification of suicidal behavior.
Time frame: Overall post Open-label Baseline treatment period (26 weeks)
Time to Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856
Relapse is defined as the earliest occurrence of any of the following: - An increase in PANSS total score by ≥ 30% from the PANSS total score at clinical response and a CGI-S score ≥ 3; - Re-hospitalization for worsening of psychosis; - Emergence of suicidality, homicidality, and/or risk of harm to self or others.
Time frame: From the time of clinical response to relapse or censor (one day after the last study drug dose)
Rate of Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856
Relapse is defined as the earliest occurrence of any of the following: - An increase in PANSS total score by ≥ 30% from the PANSS total score at clinical response and a CGI-S score ≥ 3; - Re-hospitalization for worsening of psychosis; - Emergence of suicidality, homicidality, and/or risk of harm to self or others.
Time frame: From the time of clinical response to relapse or censor (one day after the last study drug dose)
Changes From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Positive and Negative Syndrome Scale (PANSS) Total Score and Subscale Scores (Positive, Negative, and General Psychopathology)
PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.
Time frame: Double-blind Baseline (DB BLN), Open-label Baseline (OL BLN), Week 26 (Wk 26)
Change From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Clinical Global Impression - Severity (CGI-S) Score
The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.
Time frame: Double-blind (DB) Baseline, Open-label (OL) Baseline, Week 26
Change From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Brief Negative Symptom Scale (BNSS) Total Score
The BNSS is a rating scale to measure the current level of severity of negative symptoms in schizophrenia and schizoaffective disorder. The measure is comprised of 13 individual items organized in 6 subscales. The 13 individual items provide a composite total score (ranging from 0 to 78). Each of the items are scored on a Likert-type 7-point scale from 0 - 6, where values of 0 indicates symptom is absent and a value of 6 means the symptom is a severe form.
Time frame: Double-blind (DB) Baseline, Open-label (OL) Baseline, Week 26
Change From Double-blind Baseline of Study SEP361-201 and Open-label Baseline of Study SEP361-202 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
The MADRS is a clinician-rated assessment of the subject's level of depression. The measure contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal thoughts. Each item is scored in a range of 0 to 6 points, with higher scores indicating increased depressive symptoms. Total score will be equal to the sum of the 10 items (range between 0 and 60).
Time frame: Double-blind (DB) Baseline, Open-label (OL) Baseline, Week 26
Proportion of Subjects Who Achieved a Response, Defined as a 20% or Greater Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score From Double-blind Baseline of Study SEP361-201
PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.
Time frame: Week 26
| Milestone | SEP-363856 |
|---|---|
| Started | 157 |
| Subjects who received study medication | 156 |
| Completed | 105 |
| Not completed | 52 |
| Withdrew: Adverse event | 18 |
| Withdrew: Lack of efficacy | 8 |
| Withdrew: Non-compliance with study drug | 1 |
| Withdrew: Investigator considers subject clinically unstable, not appropriate for discharge to an outpatient | 1 |
| Withdrew: Sponsor request that subject be withdrawn due to positive drug results and for the subject's safety | 1 |
| Withdrew: Lost to followup | 6 |
| Withdrew: Moved out of state | 1 |
| Withdrew: Withdrawal by subject | 16 |
Number of Participants with overall Adverse Events (AEs), Serious Adverse Events (SAEs), and Adverse Events (AEs) leading to discontinuation
| Participants | SEP-363856 |
|---|---|
| Overall Adverse Events (AEs) | 88 |
| Serious Adverse Events (SAEs) | 15 |
| Adverse Events leading to discontinuation from study | 18 |
| Adverse Events leading to discontinuation of study drug | 18 |
Number of participants with suicidal ideation (SI) and suicidal behavior (SB) using the Columbia - Suicide Severity Rating Scale (C-SSRS). The C-SSRS is a tool designed to systematically assess and track suicidal behavior and suicidal ideation for life time, one month prior to the screening visit for suicidal ideation and 6 months prior to the screening visit for suicidal behavior, and throughout the study. The strength of this suicide classification system is in its ability to comprehensively identify suicidal events while limiting the over-identification of suicidal behavior.
| Participants | SEP-363856 |
|---|---|
| Any suicidal ideation | 3 |
| Any suicidal behavior | 1 |
| Any suicidality | 3 |
The C-SSRS is a tool designed to systematically assess and track suicidal behavior and suicidal ideation for life time, one month prior to the screening visit for suicidal ideation and 6 months prior to the screening visit for suicidal behavior, and throughout the study. The strength of this suicide classification system is in its ability to comprehensively identify suicidal events while limiting the over-identification of suicidal behavior.
| Participants | SEP-363856 |
|---|---|
| SI: Wish to be dead | 2 |
| SI: Non-specific active suicidal thoughts | 2 |
| SI: Any methods (not plan) without intent to act | 0 |
| SI: Some intent to act, without specific plan | 0 |
| SI: Specific plan and intent | 0 |
| SB: Preparatory acts or behavior | 0 |
| SB: Aborted attempt | 1 |
| SB: Interrupted attempt | 0 |
| SB: Actual attempt (non-fatal) | 0 |
| SB: Completed suicide | 0 |
Relapse is defined as the earliest occurrence of any of the following: - An increase in PANSS total score by ≥ 30% from the PANSS total score at clinical response and a CGI-S score ≥ 3; - Re-hospitalization for worsening of psychosis; - Emergence of suicidality, homicidality, and/or risk of harm to self or others.
| Days | PBO-SEP | SEP-SEP |
|---|---|---|
| Time to Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856 | NA (NA to NA) | NA (NA to NA) |
Relapse is defined as the earliest occurrence of any of the following: - An increase in PANSS total score by ≥ 30% from the PANSS total score at clinical response and a CGI-S score ≥ 3; - Re-hospitalization for worsening of psychosis; - Emergence of suicidality, homicidality, and/or risk of harm to self or others.
| Participants | PBO-SEP | SEP-SEP |
|---|---|---|
| Rate of Relapse During the 26-week Open-label Treatment Period for Subjects Who Demonstrated a Clinical Response to 4 Weeks of Treatment With SEP-363856 | 12 | 11 |
PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.
| Units on a scale | SEP-363856 |
|---|---|
| Total Score: DB BLN Observed | 101.5 ± 7.99 |
| Total Score: OL BLN Observed | 83.1 ± 15.03 |
| Total Score: Wk 26 Observed | 59.3 ± 12.45 |
| Total Score: Chg from DB BLN at Wk 26 | -41.8 ± 13.98 |
| Total Score: Chg from OL BLN at Wk 26 | -22.6 ± 15.48 |
| Positive SS: DB BLN Observed | 25.7 ± 3.22 |
| Positive SS: OL BLN Observed | 19.8 ± 4.96 |
| Positive SS: Wk 26 Observed | 12.2 ± 3.72 |
| Positive SS: Chg from DB BLN at Wk 26 | -13.5 ± 4.75 |
| Positive SS: Chg from OL BLN at Wk 26 | -7.3 ± 5.37 |
| Negative SS: DB BLN Observed | 25.4 ± 4.03 |
| Negative SS: OL BLN Observed | 22.3 ± 4.38 |
| Negative SS: Wk 26 Observed | 17.2 ± 4.10 |
| Negative SS: Chg from DB BLN at Wk 26 | -8.4 ± 4.48 |
| Negative SS: Chg from OL BLN at Wk 26 | -5.2 ± 4.20 |
| Gen-Psychopathology SS: DB BLN Observed | 50.4 ± 5.01 |
| Gen-Psychopathology SS: OL BLN Observed | 41.1 ± 7.93 |
| Gen-Psychopathology SS: Wk 26 Observed | 30.0 ± 6.77 |
| Gen-Psychopathology SS: Chg from DB BLN at Wk 26 | -19.9 ± 7.86 |
| Gen-Psychopathology SS: Chg from OL BLN at Wk 26 | -10.2 ± 8.31 |
The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.
| Units on a scale | SEP-363856 |
|---|---|
| CGI-S Score: DB Baseline Observed | 5.0 ± 0.42 |
| CGI-S Score: OL Baseline Observed | 4.0 ± 0.84 |
| CGI-S Score: Week 26 Observed | 3.0 ± 0.74 |
| CGI-S Score: Change from DB Baseline at Week 26 | -2.0 ± 0.82 |
| CGI-S Score: Change from OL Baseline at Week 26 | -1.0 ± 0.91 |
The BNSS is a rating scale to measure the current level of severity of negative symptoms in schizophrenia and schizoaffective disorder. The measure is comprised of 13 individual items organized in 6 subscales. The 13 individual items provide a composite total score (ranging from 0 to 78). Each of the items are scored on a Likert-type 7-point scale from 0 - 6, where values of 0 indicates symptom is absent and a value of 6 means the symptom is a severe form.
| Units on a scale | SEP-363856 |
|---|---|
| Total Score: DB Baseline Observed | 38.4 ± 11.94 |
| Total Score: OL Baseline Observed | 33.0 ± 11.41 |
| Total Score: Week 26 Observed | 22.5 ± 11.83 |
| Total Score: Change from DB Baseline at Week 26 | -16.8 ± 12.42 |
| Total Score: Change from OL Baseline at Week 26 | -11.3 ± 9.69 |
The MADRS is a clinician-rated assessment of the subject's level of depression. The measure contains 10 items that measure apparent and reported sadness, inner tension, reduced sleep and appetite, difficulty concentrating, lassitude, inability to feel, and pessimistic and suicidal thoughts. Each item is scored in a range of 0 to 6 points, with higher scores indicating increased depressive symptoms. Total score will be equal to the sum of the 10 items (range between 0 and 60).
| Units on a scale | SEP-363856 |
|---|---|
| Total Score: DB Baseline Observed | 12.6 ± 7.25 |
| Total Score: OL Baseline Observed | 9.2 ± 6.33 |
| Total Score: Week 26 Observed | 4.4 ± 4.72 |
| Total Score: Change from DB Baseline at Week 26 | -8.1 ± 6.44 |
| Total Score: Change from OL Baseline at Week 26 | -4.5 ± 5.28 |
PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.
| Participants | PBO-SEP | SEP-SEP |
|---|---|---|
| Proportion of Subjects Who Achieved a Response, Defined as a 20% or Greater Improvement in Positive and Negative Syndrome Scale (PANSS) Total Score From Double-blind Baseline of Study SEP361-201 | 52 | 49 |
Collected over From first dose of study drug to last study visit (27 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SEP-363856 | 0/156 (0%) | 15/156 (9.6%) | 39/156 (25%) |
| Event | SEP-363856 |
|---|---|
| SchizophreniaPsychiatric disorders | 11/156 |
| Acute psychosisPsychiatric disorders | 1/156 |
| DepressionPsychiatric disorders | 1/156 |
| Psychotic disorderPsychiatric disorders | 1/156 |
| Suicidal ideationPsychiatric disorders | 1/156 |
| Uterine haemorrhageReproductive system and breast disorders | 1/156 |
| Event | SEP-363856 |
|---|---|
| HeadacheNervous system disorders | 18/156 |
| InsomniaPsychiatric disorders | 13/156 |
| SchizophreniaPsychiatric disorders | 10/156 |
| AnxietyPsychiatric disorders | 8/156 |
| Age, Categorical(Participants) | SEP-363856 |
|---|---|
| <=18 years | 2 |
| Between 18 and 65 years | 154 |
| >=65 years | 0 |
| Age, Continuous(Years) | SEP-363856 |
|---|---|
| Mean | 30.2 ± 6.03 |
| Sex: Female, Male(Participants) | SEP-363856 |
|---|---|
| Female | 54 |
| Male | 102 |
| Ethnicity (NIH/OMB)(Participants) | SEP-363856 |
|---|---|
| Hispanic or Latino | 5 |
| Not Hispanic or Latino | 151 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | SEP-363856 |
|---|---|
| American Indian or Alaska Native | 4 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 15 |
| White | 136 |
| More than one race | 1 |
| Unknown or Not Reported | 0 |
| Age, Customized(Participants) | SEP-363856 |
|---|---|
| >=18 - <25 years | 38 |
| >=25 - <=40 years | 118 |
| Country(Participants) | SEP-363856 |
|---|---|
| Hungary | 8 |
| Romania | 6 |
| Russia | 68 |
| Ukraine | 54 |
| United States | 20 |
| Double-blind Baseline BMI (Body Mass Index) Group(Participants) | SEP-363856 |
|---|---|
| <18.5 kg/m^2 | 2 |
| >=18.5 - <25.0 kg/m^2 | 80 |
| >=25.0 - <30.0 kg/m^2 | 55 |
| >=30.0 kg/m^2 | 19 |
9 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized Individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Access criteria: Otsuka will share data on the Vivli data sharing platform which can be found here: https://vivli.org/ourmember/Otsuka/
Data sharing details ↗ · clinical-trials.otsuka.com
Ran from Jan 2017 to primary completion in Jan 2019, 23 months.
Results were first posted in Feb 2022, 3 years after primary completion. A results delay was requested in Dec 2019.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's 23 months is above that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SEP-363856
Otsuka Pharmaceutical Development & Commercialization, Inc. →